HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors

· 2025-10-14

Funding

NCI NIH HHS

P30 CA008748

Daiichi Sankyo Company, Limited

Merck Sharp & Dohme LLC